Physician profile
Andras Schaffer
NPI 1578626677
$2,605.56
in general payments reported to CMS, 2019-2025
16 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $1,260 · 2024: $727 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,481.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $462.11 | 2023-2025 | |
| Ucb, INC. | $317.51 | 2023-2024 | Cimzia, Bimzelx |
| Dermavant Sciences, INC. | $297.51 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $274.95 | 2022-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $236.99 | 2023-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $235.22 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $193.15 | 2024-2025 | Zoryve |
| Incyte Corporation | $166.84 | 2024-2025 | |
| Abbvie INC. | $123.03 | 2023 | Rinvoq |
| Leo Pharma INC. | $83.73 | 2024 | Adbry |
| Kyowa Kirin, INC. | $66.11 | 2024 | Poteligeo |
| Genentech, INC. | $50.00 | 2023 | Xolair |
| Smith+Nephew, INC. | $38.84 | 2023 | Oasis, Grafix Pl |
| Organogenesis INC. | $25.81 | 2023 | Puraply |
| Lilly USA, LLC | $22.31 | 2025 | Ebglyss |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $11.45 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andras Schaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.